Literature DB >> 9378493

The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers.

M W Bleeker1, M G Netea, B J Kullberg, J Van der Ven-Jongekrijg, J W Van der Meer.   

Abstract

Tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) are pro-inflammatory cytokines that play an important role in severe infections, whereas IL-1 receptor antagonist (IL-1ra) and IL-10 are anti-inflammatory cytokines that counteract their effects. Chlorpromazine and dexamethasone protect mice against lethal endotoxaemia by decreasing circulating concentrations of TNF-alpha and IL-1 beta. We investigated whether administration of chlorpromazine or dexamethasone to human volunteers is able to modulate the lipopolysaccharide (LPS)-stimulated cytokine production capacity in whole blood. Blood samples were taken before and several time-points after medication. Circulating cytokine concentrations were low in all samples. LPS-induced TNF-alpha and IL-1 beta production in whole blood was inhibited by dexamethasone treatment, while chlorpromazine had no effect. When peripheral blood mononuclear cells were stimulated in vitro with LPS, the addition of chlorpromazine (1-100 ng/ml) had no modulatory action on TNF-alpha, IL-1 beta, IL-1ra or IL-10 synthesis. The chlorpromazine concentrations measured in circulation of volunteers were eight to 40 times lower than the concentrations shown to be effective in mice. In conclusion, chlorpromazine inhibits TNF-alpha and IL-1 beta production in mice at concentrations that cannot be reached in humans, thus precluding its usage in clinical anti-cytokine strategies. In contrast, dexamethasone is an effective inhibitor of pro-inflammatory cytokine production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378493      PMCID: PMC1363874          DOI: 10.1046/j.1365-2567.1997.00285.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  The effects of selected drugs, including chlorpromazine and non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro.

Authors:  F Martinez; J W Coleman
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes.

Authors:  M J Schleuning; A Duggan; G H Reem
Journal:  Eur J Immunol       Date:  1989-08       Impact factor: 5.532

3.  Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes.

Authors:  A Waage; O Bakke
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

4.  Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor.

Authors:  S Endres; R Ghorbani; G Lonnemann; J W van der Meer; C A Dinarello
Journal:  Clin Immunol Immunopathol       Date:  1988-12

5.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

6.  Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo.

Authors:  R Tarazona; A González-García; N Zamzami; P Marchetti; N Frechin; J A Gonzalo; M Ruiz-Gayo; N van Rooijen; C Martínez; G Kroemer
Journal:  J Immunol       Date:  1995-01-15       Impact factor: 5.422

7.  Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms.

Authors:  J A Kern; R J Lamb; J C Reed; R P Daniele; P C Nowell
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

8.  A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.

Authors:  G Wakabayashi; J A Gelfand; J F Burke; R C Thompson; C A Dinarello
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

9.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock.

Authors:  M Gadina; R Bertini; M Mengozzi; M Zandalasini; A Mantovani; P Ghezzi
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

10.  Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor.

Authors:  R Bertini; M Bianchi; P Ghezzi
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

2.  Delta-aminolevulinic acid dehydratase polymorphism and the relation between low level lead exposure and the Mini-Mental Status Examination in older men: the Normative Aging Study.

Authors:  J Weuve; K T Kelsey; J Schwartz; D Bellinger; R O Wright; P Rajan; A Spiro; D Sparrow; A Aro; H Hu
Journal:  Occup Environ Med       Date:  2006-06-06       Impact factor: 4.402

3.  Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

Authors:  P Barrera; L A Joosten; A A den Broeder; L B van de Putte; P L van Riel; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2001-07       Impact factor: 19.103

4.  Defective interleukin-1 receptor antagonist production is associated with resistance of acute liver graft rejection to steroid therapy.

Authors:  F Conti; S Breton; F Batteux; V Furlan; D Houssin; B Weill; Y Calmus
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

5.  Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 beta levels in the rat brain.

Authors:  Ewa Obuchowicz; Agnieszka Marcinowska; Lukasz Drzyzga; Jacek Wójcikowski; Władysława A Daniel; Zbigniew S Herman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-01       Impact factor: 3.000

6.  The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production.

Authors:  A C Peeters; M G Netea; B J Kullberg; T Thien; J W van der Meer
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

7.  A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages.

Authors:  Catriona M Turnbull; Paolo Marcarino; Tara A Sheldrake; Loretta Lazzarato; Clara Cena; Roberta Fruttero; Alberto Gasco; Sarah Fox; Ian L Megson; Adriano G Rossi
Journal:  J Inflamm (Lond)       Date:  2008-07-31       Impact factor: 4.981

8.  Immunomodulatory nanodiamond aggregate-based platform for the treatment of rheumatoid arthritis.

Authors:  Amanda Pentecost; Min Ju Kim; Sangmin Jeon; Young Ji Ko; Ick Chan Kwon; Yury Gogotsi; Kwangmeyung Kim; Kara L Spiller
Journal:  Regen Biomater       Date:  2019-04-19

9.  Changes In Plasma NPY, IL-1β And Hypocretin In People Who Died By Suicide.

Authors:  Jing Lu; Shangda Li; Haimei Li; Tingting Mou; Lihong Zhou; Bochao Huang; Manli Huang; Yi Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2019-10-10       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.